eczema

Apogee claims IL-13 antibody sets new eczema treatment standard

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main goal of a phase 2 trial.

James Waldron Jul 7, 2025 8:29am

An arrow incrementally going up stairs before pointing straight up Blue background

Leo's eczema prospect hits primary endpoint in phase 2b

May 9, 2025 7:30am

rocket launch satellite space fly blast off

Amgen ignites Rocket program with wins in phase 3 eczema trials

Mar 10, 2025 5:48am

Person throwing piece of paper into full waste bin

Anaptys scraps atopic dermatitis asset after ph. 2 fail

Dec 11, 2024 11:02am

target reach ladder climb meet win beat competition

Amgen reports first phase 3 win for $400M eczema drug

Sep 25, 2024 5:50am

Connect uncouples from Pfizer by scrapping eczema pact

Apr 17, 2024 6:38am